Understanding Diabetic Eye Disease and Its Global Burden

Diabetic eye disease, particularly diabetic retinopathy (DR), remains one of the leading causes of preventable blindness among working-age adults worldwide. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, and about one-third of them have some form of diabetic retinopathy. The condition results from chronic hyperglycemia, which damages the retinal microvasculature, leading to capillary leakage, occlusion, and ischemia. Over time, this triggers the release of vascular endothelial growth factor (VEGF) and other inflammatory mediators, promoting abnormal blood vessel growth and macular edema — the primary drivers of vision loss.

Diabetic macular edema (DME), a common complication of DR, occurs when fluid accumulates in the macula, the central part of the retina responsible for sharp vision. Without timely intervention, DME can cause irreversible structural damage and significant visual impairment. Traditional management has relied on glycemic control, blood pressure management, and laser photocoagulation. However, advances in pharmacotherapy — particularly intraocular injections — have transformed the treatment landscape.

What Is Triple Therapy for Diabetic Eye Disease?

Triple therapy refers to a multimodal treatment strategy that combines three distinct therapeutic modalities to target different pathogenic pathways in diabetic retinopathy and DME. The three components are:

  • Anti-VEGF injections – to neutralize VEGF and reduce angiogenesis and vascular leakage.
  • Corticosteroid injections or implants – to suppress inflammation and stabilize the blood-retinal barrier.
  • Laser photocoagulation – to ablate ischemic retina and reduce oxygen demand, thereby decreasing VEGF production.

The rationale for combining these treatments is compelling. Diabetic retinopathy is a complex disease involving angiogenesis, inflammation, and neurodegeneration. A single-agent approach may not adequately address all components. Triple therapy allows clinicians to tackle multiple mechanisms simultaneously, potentially achieving better anatomical and functional outcomes than monotherapy. For instance, anti-VEGF agents rapidly reduce edema, while steroids provide sustained anti-inflammatory effects, and laser treatment addresses underlying ischemia. This synergistic approach is particularly valuable in eyes that respond poorly to first‑line anti-VEGF monotherapy.

Evolving Evidence Supporting Triple Therapy

Several clinical studies have investigated the efficacy of triple therapy. The DRCR.net Protocol T and subsequent analyses have shown that while anti-VEGF drugs alone are effective, some patients — especially those with chronic DME or preexisting vitreomacular traction — benefit from adding steroids. Laser therapy, long the standard of care, continues to play a role in managing proliferative DR and reducing the treatment burden when combined with injections. A 2022 meta-analysis published in JAMA Ophthalmology found that combination therapy (anti-VEGF plus corticosteroid) yielded superior visual acuity gains and greater reduction in central subfield thickness compared to anti-VEGF alone in eyes with refractory DME. The advent of longer-acting steroid implants like dexamethasone (Ozurdex) and fluocinolone acetonide (Iluvien) has made combination regimens more practical.

The Central Role of Intraocular Injections in Triple Therapy

Intraocular injections are the cornerstone of delivering medications directly into the vitreous cavity. They enable high local drug concentrations with minimal systemic exposure, which is critical for patients with diabetes who often have comorbidities like renal impairment that limit systemic therapy. Two main classes of agents are used: anti-VEGF and corticosteroids.

Anti-VEGF Injections: Mechanism and Agents

VEGF is a key driver of vascular permeability and neovascularization in diabetic eye disease. Anti-VEGF drugs bind to VEGF isoforms and prevent receptor activation, thereby reducing leakage and abnormal vessel growth. The three most commonly used agents are:

  • Bevacizumab (Avastin) – a full-length monoclonal antibody; widely used off-label due to low cost; effective but requires frequent injections.
  • Ranibizumab (Lucentis) – an antibody fragment designed for ocular use; approved for DME and DR; shorter half-life but potent.
  • Aflibercept (Eylea) – a VEGF receptor-Fc fusion protein with higher binding affinity; allows extended dosing intervals in many patients.

More recently, faricimab (Vabysmo), a bispecific antibody targeting both VEGF‑A and Ang‑2, has shown promise in reducing injection frequency while maintaining efficacy. Clinical trials reported that faricimab achieved non‑inferior visual gains compared to aflibercept with every‑16‑week dosing in many patients.

Corticosteroid Injections: The Anti‑Inflammatory Arm

Corticosteroids inhibit multiple inflammatory pathways, including prostaglandin synthesis and leukocyte adhesion. They stabilize the blood‑retinal barrier and reduce macular edema through glucocorticoid receptor‑mediated effects. Steroid formulations used in triple therapy include:

  • Dexamethasone intravitreal implant (Ozurdex) – releases dexamethasone over 4–6 months; indicated for DME and uveitis; commonly used in combination with anti-VEGF.
  • Fluocinolone acetonide intravitreal implant (Iluvien) – provides sustained release for up to 3 years; reserved for chronic DME non‑responsive to other treatments; carries higher risk of elevated intraocular pressure (IOP) and cataract.
  • Triamcinolone acetonide (Kenalog) – used historically; effect lasts 2–4 months; less commonly employed now due to safety profile.

Steroids are particularly valuable in eyes with significant inflammation, vitreomacular interface abnormalities, or previous vitrectomy where anti-VEGF diffusion may be impaired. The synergy with anti-VEGF agents is well documented: steroids dampen the inflammatory milieu that upregulates VEGF, potentially reducing the total number of needed injections.

Advantages of Intraocular Injections in Triple Therapy

The integration of intraocular injections with laser photocoagulation provides several distinct benefits:

  • Rapid anatomical improvement: Anti-VEGF injections often produce a measurable reduction in central macular thickness within days.
  • Targeted therapy with minimal systemic impact: The vitreous cavity acts as a reservoir, keeping drug concentrations high in the target tissue while systemic absorption is limited.
  • Flexibility in dosing: Clinicians can tailor injection intervals based on disease activity, using treat‑and‑extend protocols to optimize outcomes while minimizing visits.
  • Synergy with laser: Injections reduce edema and neovascularization, making subsequent laser treatment more effective and less destructive to healthy retina.
  • Potential for visual acuity gains: Numerous studies report that combination therapy produces greater mean visual acuity improvements than either modality alone, especially in patients with baseline severe vision loss.

Practical Implementation in the Clinic

A typical triple therapy protocol might involve an initial loading phase of monthly anti-VEGF injections combined with a steroid implant (e.g., dexamethasone), followed by laser photocoagulation to areas of peripheral ischemia. After the laser, many patients can be extended to 8‑ or 12‑week intervals on anti-VEGF alone. Steroid implants are often reserved for eyes that have persistent or recurrent edema despite anti-VEGF therapy. The decision to use steroids must account for the patient’s lens status (phakic vs. pseudophakic) and baseline IOP, as steroids accelerate cataract formation and can cause steroid‑induced glaucoma.

Challenges and Considerations in Triple Therapy

Despite the advantages, intraocular injections are not without risks and limitations. The most serious adverse event is endophthalmitis, a devastating intraocular infection that occurs in approximately 1 in 2,000 to 5,000 injections. Strict aseptic technique — including povidone‑iodine antisepsis, lid speculum use, and avoidance of contamination — is essential. Other common complications include:

  • Elevated intraocular pressure (IOP) – particularly with steroids; requires monitoring and sometimes IOP‑lowering medications or surgical intervention.
  • Subconjunctival hemorrhage – usually self‑limited.
  • Cataract progression – accelerated by steroids; may necessitate future cataract surgery.
  • Retinal detachment or lens injury – rare but possible with improper needle placement.
  • Patient discomfort and treatment burden – frequent injections can be stressful and logistically challenging for patients with limited access to care.

Moreover, triple therapy must be embedded within comprehensive diabetes management. Strict glycemic control, blood pressure regulation, and lipid management are foundational. Even the most sophisticated injection regimen cannot compensate for poorly controlled systemic disease. The American Diabetes Association recommends that patients with diabetes undergo annual dilated eye exams and that those with DR receive timely referral to a retina specialist.

Patient Selection and Individualization

Not every patient with diabetic eye disease is a candidate for triple therapy. Factors influencing the choice include:

  • Severity of DR and DME: Mild non‑proliferative DR may respond to laser alone; triple therapy is typically reserved for moderate to severe cases with center‑involving DME.
  • Lens status: Phakic patients may avoid steroids or opt for a shorter‑acting implant to minimize cataract risk.
  • Prior treatment response: Eyes that have failed anti‑VEGF monotherapy are prime candidates for adding steroids and laser.
  • Cost and access: Bevacizumab is far less expensive than ranibizumab or aflibercept, which influences real‑world choices, especially in public health systems.

Future Directions: Next‑Generation Therapies and Personalized Regimens

Research into diabetic eye disease continues to evolve. Emerging therapies include gene therapy, sustained‑release implants with longer duration, and new molecular targets such as complement inhibitors and integrin antagonists. The goal is to reduce injection frequency further while maintaining or improving efficacy. For example, the Port Delivery System (PDS) with ranibizumab, a refillable implant, allows up to 6‑month dosing intervals. Additionally, artificial intelligence‑based screening tools are improving early detection, enabling earlier intervention with triple therapy before irreversible damage occurs.

Personalized medicine is also gaining traction. Genetic and biomarker profiling may soon help identify which patients are most likely to benefit from anti‑VEGF alone, steroids, or combination therapy. In the meantime, triple therapy with intraocular injections remains a powerful and widely used strategy for managing advanced diabetic eye disease.

Conclusion

Intraocular injections are an indispensable component of triple therapy for diabetic eye disease. By delivering anti-VEGF agents and corticosteroids directly to the retina, these injections provide targeted, potent treatment that can rapidly reduce edema, control neovascularization, and preserve vision. When combined with laser photocoagulation, they address the multifactorial nature of diabetic retinopathy more effectively than any single modality alone. However, success depends on careful patient selection, meticulous injection technique, and diligent management of systemic risk factors. As research continues to refine these approaches, intraocular injections will remain at the forefront of efforts to combat vision loss from diabetes.

For further reading, refer to the American Academy of Ophthalmology – Diabetic Retinopathy Summary, the National Eye Institute’s page on diabetic retinopathy, and the American Diabetes Association’s eye complication resources.